Biosyent Inc (TSE:RX)
:RX
Total Valuation
Biosyent has a market cap or net worth of C$170.97M. The enterprise value is C$151.52M.
Market CapC$170.97M
Enterprise ValueC$151.52M
Share Statistics
Biosyent has 11,497,447 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding11,497,447
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Biosyent’s return on equity (ROE) is 0.22 and return on invested capital (ROIC) is 19.97%.
Return on Equity (ROE)0.22
Return on Assets (ROA)0.18
Return on Invested Capital (ROIC)19.97%
Return on Capital Employed (ROCE)0.27
Revenue Per Employee717.53K
Profits Per Employee150.20K
Employee Count60
Asset Turnover0.87
Inventory Turnover1.71
Valuation Ratios
The current PE Ratio of Biosyent is 15.9. Biosyent’s PEG ratio is 0.59.
PE Ratio15.9
PS Ratio3.33
PB Ratio3.46
Price to Fair Value3.46
Price to FCF14.99
Price to Operating Cash Flow17.93
PEG Ratio0.59
Income Statement
In the last 12 months, Biosyent had revenue of 43.05M and earned 9.01M in profits. Earnings per share was 0.80.
Revenue43.05M
Gross Profit32.11M
Operating Income11.31M
Pretax Income12.03M
Net Income9.01M
EBITDA12.17M
Earnings Per Share (EPS)0.80
Cash Flow
In the last 12 months, operating cash flow was 9.34M and capital expenditures -386.17K, giving a free cash flow of 8.95M billion.
Operating Cash Flow9.34M
Free Cash Flow8.95M
Free Cash Flow per Share0.78
Dividends & Yields
Biosyent pays an annual dividend of C$0.05, resulting in a dividend yield of 1.6%
Dividend Per ShareC$0.05
Dividend Yield1.6%
Payout Ratio26.67%
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.68
52-Week Price Change50.38%
50-Day Moving Average14.61
200-Day Moving Average12.38
Relative Strength Index (RSI)49.07
Average Volume (3m)5.67K
Important Dates
Biosyent upcoming earnings date is May 14, 2026, TBA (Confirmed).
Last Earnings DateMar 19, 2026
Next Earnings DateMay 14, 2026
Ex-Dividend Date―
Financial Position
Biosyent as a current ratio of 5.51, with Debt / Equity ratio of 2.03%
Current Ratio5.51
Quick Ratio4.63
Debt to Market Cap<0.01
Net Debt to EBITDA-1.60
Interest Coverage Ratio229.23
Taxes
In the past 12 months, Biosyent has paid 3.02M in taxes.
Income Tax3.02M
Effective Tax Rate0.25
Enterprise Valuation
Biosyent EV to EBITDA ratio is 10.19, with an EV/FCF ratio of 12.95.
EV to Sales2.88
EV to EBITDA10.19
EV to Free Cash Flow12.95
EV to Operating Cash Flow12.88
Balance Sheet
Biosyent has C$28.65M in cash and marketable securities with C$841.10K in debt, giving a net cash position of C$27.81M billion.
Cash & Marketable SecuritiesC$28.65M
Total DebtC$841.10K
Net CashC$27.81M
Net Cash Per ShareC$2.42
Tangible Book Value Per ShareC$3.26
Margins
Gross margin is 76.04%, with operating margin of 26.28%, and net profit margin of 20.93%.
Gross Margin76.04%
Operating Margin26.28%
Pretax Margin27.94%
Net Profit Margin20.93%
EBITDA Margin28.26%
EBIT Margin26.28%
Analyst Forecast
The average price target for Biosyent is C$16.50, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price TargetC$16.50
Price Target Upside10.96% Upside
Analyst ConsensusModerate Buy
Analyst Count1
Revenue Growth Forecast22.22%
EPS Growth Forecast25.50%